Our Services

Alzheimer’s Disease

Alzheimer's is the most common form of dementia, a general term for memory loss and other intellectual abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60 to 80 percent of dementia cases. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment.

Early Alzheimer's Disease Immunotherapy Trial

  • Study name: “EMERGE”
  • Patients receive either Aducanumab (BIIB037) or placebo
  • Main study doctor (Principal Investigator): Alan Bernstein, MD
  • For more information, please contact the lead coordinator, Terry Hess, at 707-521-3826 or at Terry.Hess@stjoe.org